CALLIDITAS THERAPEUTICS ABCALLIDITAS THERAPEUTICS ABCALLIDITAS THERAPEUTICS AB

CALLIDITAS THERAPEUTICS AB

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪10.99 B‬SEK
‪−466.19 M‬SEK
‪1.21 B‬SEK
‪11.73 M‬
Beta (1Y)
0.01

About CALLIDITAS THERAPEUTICS AB

CEO
Renée Julie Elisabet Aguiar-Lucander
Headquarters
Stockholm
Employees (FY)
217
Founded
2004
ISIN
SE0010441584
FIGI
BBG00B4MYMF0
Calliditas Therapeutics AB clinical-stage biopharmaceutical company. It engages in the identification, development, and commercialization of novel treatments in orphan indications. The firm focuses on renal and hepatic diseases with significant unmet medical needs. It offers Nefecon, a proprietary, novel oral formulation of budesonide for the treatment of the autoimmune renal disease IgA nephropathy, or IgAN. The firm product TARPEYO is used to reduce proteinuria in adults with primary immunoglobulin. The company was founded by Mikael Bender and Bengt Åke Julander on February 20, 2004 and is headquartered in Stockholm, Sweden.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of CALTX is 205.6 SEK — it has increased by 0.39% in the past 24 hours. Watch CALLIDITAS THERAPEUTICS AB stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on OMXSTO exchange CALLIDITAS THERAPEUTICS AB stocks are traded under the ticker CALTX.
CALTX stock has risen by 0.29% compared to the previous week, the month change is a 68.66% rise, over the last year CALLIDITAS THERAPEUTICS AB has showed a 118.72% increase.
We've gathered analysts' opinions on CALLIDITAS THERAPEUTICS AB future price: according to them, CALTX price has a max estimate of 270.00 SEK and a min estimate of 177.00 SEK. Watch CALTX chart and read a more detailed CALLIDITAS THERAPEUTICS AB stock forecast: see what analysts think of CALLIDITAS THERAPEUTICS AB and suggest that you do with its stocks.
CALTX reached its all-time high on May 30, 2024 with the price of 208.8 SEK, and its all-time low was 39.2 SEK and was reached on Nov 28, 2018. View more price dynamics on CALTX chart.
See other stocks reaching their highest and lowest prices.
CALTX stock is 0.68% volatile and has beta coefficient of 0.01. Track CALLIDITAS THERAPEUTICS AB stock price on the chart and check out the list of the most volatile stocks — is CALLIDITAS THERAPEUTICS AB there?
Today CALLIDITAS THERAPEUTICS AB has the market capitalization of ‪10.99 B‬, it has decreased by 0.68% over the last week.
Yes, you can track CALLIDITAS THERAPEUTICS AB financials in yearly and quarterly reports right on TradingView.
CALLIDITAS THERAPEUTICS AB is going to release the next earnings report on Aug 13, 2024. Keep track of upcoming events with our Earnings Calendar.
CALTX earnings for the last quarter are −4.59 SEK per share, whereas the estimation was −0.98 SEK resulting in a −366.38% surprise. The estimated earnings for the next quarter are −0.44 SEK per share. See more details about CALLIDITAS THERAPEUTICS AB earnings.
CALLIDITAS THERAPEUTICS AB revenue for the last quarter amounts to ‪295.50 M‬ SEK, despite the estimated figure of ‪370.82 M‬ SEK. In the next quarter, revenue is expected to reach ‪462.63 M‬ SEK.
CALTX net income for the last quarter is ‪−246.16 M‬ SEK, while the quarter before that showed ‪−18.37 M‬ SEK of net income which accounts for ‪−1.24 K‬% change. Track more CALLIDITAS THERAPEUTICS AB financial stats to get the full picture.
No, CALTX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jun 25, 2024, the company has 217.00 employees. See our rating of the largest employees — is CALLIDITAS THERAPEUTICS AB on this list?
Like other stocks, CALTX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade CALLIDITAS THERAPEUTICS AB stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So CALLIDITAS THERAPEUTICS AB technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating CALLIDITAS THERAPEUTICS AB stock shows the buy signal. See more of CALLIDITAS THERAPEUTICS AB technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.